Synthesis and structure-activity relationships of 4-oxo-1-phenyl- 3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: Novel PDE4 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 1, 2000, Pages 35-38

  Pascal, Yves ^a   Andrianjara, Charles R ^a   Auclair, Eric ^a   Avenel, Nadine ^a   Bertin, Bernadette ^a   Calvet, Alain ^d   Féru, Frédéric ^a   Lardon, Sophie ^a   Moodley, Indres ^b   Ouagued, Malika ^a   Payne, Adrian ^c   Pruniaux, Marie Pierre ^a   Szilagyi, Corinne ^a  

^a Institut de Recherche Jouveinal   (France)

^b Univ of W   (South Africa)

^c BRITISH AMERICAN TOBACCO   (United Kingdom)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 INDOLYL)CARBOXYLAMINO 4 OXO 1 PHENYL 3,4,6,7 TETRAHYDRO[1,4]DIAZEPINO[6,7,1 HI]INDOLE; 4 OXO 1 PHENYL 3,4,6,7 TETRAHYDRO[1,4]DIZEPINO[6,7,1 HI]INDOLE; BENZODIAZEPINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BENZODIAZEPINES; BINDING SITES; DOGS; GUINEA PIGS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, INBRED BN; RATS, WISTAR; ROLIPRAM; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; U937 CELLS;

ANIMALIA; CANIS FAMILIARIS; RATTUS NORVEGICUS;

EID: 0034598340     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00573-9     Document Type: Article

References (14)

1. Beavo J.A. Physiol. Rev. 75:1995;725.
2. Palfreyman M.N. Drugs Future. 20:1995;793.
3. Palacios J.M., Beleta J., Segarra V. Il Farmaco. 50:1995;819.
4. Underwood D.C., Osborn R.R., Novak L.B., Matthews J.K., Newsholme S.J., Undem B.J., Hand J.M., Torphy T.J. J. Pharmacol. Exp. Ther. 266(1):1993;306.
5. Sawanishi H., Suzuki H., Yamamoto S., Waki Y., Kasugai S., Ohya K., Susuki N., Miyamoto K., Tagaki K. J. Med. Chem. 40:1997;3248.
6. Schmieden R., Schneider H.H., Wachtel H. Psychopharmacology. 102:1990;17.
7. Barnette, M. S.; Torphy, T. T.; Christensen, S. B. Compounds 1995 WO 00139.
8. Duplantier A.J., Biggers M.S., Chambers R.J., Cheng J.B., Cooper K., Damon D.B., Eggler J.F., Kraus K.G., Marfat A., Masamune H., Pillar J.S., Shirley J.T., Umland J.P., Watson J.W. J. Med. Chem. 39:1996;120.
9. Bock M.G., Dipardo R.M., Evans B.E., Rittle K.E., Whitter D.F., Veber P.S., Anderson P.S., Freidinger R.M. J. Med. Chem. 32:1989;13.
10. Calvet, A.; Pascal, Y.; Junien, J. L.; Pascaud, X.; Roman, F. J. Eur. Patent 340.064, 1989.
11. Satoh Y., Matsuo T., Sogabe H., Itoh H., Tada T., Kinoshita T., Yoshida K., Takaya T. Chem. Pharm. Bull. 42:1994;2071.
12. Smith B.J., Wales M.R., Jappy J.W.G., Perry M.J. Analytical Biochemistry. 214:1993;355.
13. Elwood W., Sun J., Barnes P.J., Giembycz M.A., Chung K.F. Inflammation Research. 44:1995;83.
14. Thompson W.J., Terasaki W.L., Epstein P.M., Strada S.J. Advances in Cyclic Nucleotide Research. 10:1979;69.